A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback